Redirecting glucose flux during in vitro expansion generates epigenetically and metabolically superior anti-tumor T cells for adoptive cell therapies
ChIP-seq / ATAC-seq (genome binding and open chromatin) · mouse · 28 samples
- What it is
- ChIP-seq / ATAC-seq (genome binding and open chromatin)Where proteins bind the genome, or which regions are open and active.
- Organism
- Mus musculus (mouse)
- Samples
- 28 samples: 19 distinct titles, 3 of them repeatedGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Redirecting glucose flux during in vitro expansion generates epigenetically and metabolically superior T cells for cancer immunotherapyCell metabolism · 2025
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE249771_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: Look for peak files (.bed, .narrowPeak) and signal tracks (.bigWig) among the supplementary files; the raw reads are on ENA.
Also filed as BioProject PRJNA1050304 and SRA study SRP476717. Searching any of these in the dataset finder brings you back here.
How we read this: Read from 28 sample titles: 19 distinct titles with little repetition. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM7963938 Pmel-1 T cells, untreated, Day 7, mouse 1
- GSM7963939 Pmel-1 T cells, untreated, Day 7, mouse 2
- GSM7963940 Pmel-1 T cells, untreated, Day 7, mouse 3
- GSM7963941 Pmel-1 T cells, DCA-treated, Day 7, mouse 1
- GSM7963942 Pmel-1 T cells, DCA-treated, Day 7, 2
- GSM7963943 Pmel-1 T cells, DCA-treated, Day 7, 3
- GSM7963944 Pmel-1 T cells, untreated, Day 7, mouse 1, H3K27Ac
- GSM7963945 Pmel-1 T cells, untreated, Day 7, mouse 2, H3K27Ac
- GSM7963946 Pmel-1 T cells, untreated, Day 7, mouse 3, H3K27Ac
- GSM7963947 Pmel-1 T cells, DCA-treated, Day 7, mouse 1, H3K27Ac
- GSM7963948 Pmel-1 T cells, DCA-treated, Day 7, mouse 2, H3K27Ac
- GSM7963949 Pmel-1 T cells, DCA-treated, Day 7, mouse 3, H3K27Ac
- GSM7963950 Pmel-1 T cells, untreated, Day 7, mouse 1, H3K9Ac
- GSM7963951 Pmel-1 T cells, untreated, Day 7, mouse 2, H3K9Ac
- GSM7963952 Pmel-1 T cells, untreated, Day 7, mouse 3, H3K9Ac
- GSM7963953 Pmel-1 T cells, DCA-treated, Day 7, mouse 1, H3K9Ac
- GSM7963954 Pmel-1 T cells, DCA-treated, Day 7, mouse 2, H3K9Ac
- GSM7963955 Pmel-1 T cells, DCA-treated, Day 7, mouse 3, H3K9Ac
- GSM7963956 Pmel-1 T cells, untreated, Day 7, mouse 2, H3K9Lac
- GSM7963957 Pmel-1 T cells, untreated, Day 7, mouse 3, H3K9Lac
- GSM7963958 Pmel-1 T cells, DCA-treated, Day 7, mouse 2, H3K9Lac
- GSM7963959 Pmel-1 T cells, DCA-treated, Day 7, mouse 3, H3K9Lac
- GSM7963960 Pmel-1 T cells, untreated, Day 7, mouse 1
- GSM7963961 Pmel-1 T cells, untreated, Day 7, mouse 2
- GSM7963962 Pmel-1 T cells, untreated, Day 7, mouse 3
- GSM7963963 Pmel-1 T cells, DCA-treated, Day 7, mouse 1
- GSM7963964 Pmel-1 T cells, DCA-treated, Day 7, mouse 2
- GSM7963965 Pmel-1 T cells, DCA-treated, Day 7, mouse 3
- GSE249769 Redirecting glucose flux during in vitro expansion generates epigenetically and metabolically superior anti-tumor T cells for adoptive cell therapies (CUT&Tag) 16 samples shares epigenetically, metabolically, redirecting, anti-tumor, expansion, generates, therapies, superior
- GSE282342 Aged muscle stem cells epigenetically drive the expansion of mesenchymal progenitors 48 samples shares epigenetically, expansion
- GSE329774 Metabolically and epigenetically reprogrammed splenic TRNP1hiCD8+ T cells exacerbate liver fibrosis 93 samples shares epigenetically, metabolically
- GSE250205 A PD-1-targeted, receptor-masked IL-2 immunocytokine that engages IL-2Rα strengthens T cell-mediated anti-tumor therapies 32 samples shares anti-tumor, therapies
- GSE282285 Aged muscle stem cells epigenetically drive the expansion of mesenchymal progenitors [bulk RNA-Seq] 31 samples shares epigenetically, expansion
- GSE299225 Metabolically and epigenetically reprogrammed splenic TRNP1hiCD8+ T cells exacerbate liver fibrosis 13 samples shares epigenetically, metabolically
- GSE217807 ARID1A suppresses R-loop mediated STING-Type I Interferon pathway activation of anti-tumor immunity 62 samples shares anti-tumor
- GSE298906 Succinate preserves CD8+ T cell fitness to augment anti-tumor immunity 46 samples shares anti-tumor
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.